drugset / Trial / NCT06515262
Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
Recruiting
10 enrolled
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Guangzhou Bio-gene Technology Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D CAR-T cells in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy.
Timeline
- Start
- 2024-07-01
- Primary completion
- 2026-11
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-BCMA-GPRC5D CAR-T cells | Cell therapy | — | Intravenous |